|Bid||8.74 x 1300|
|Ask||9.00 x 1400|
|Day's Range||8.50 - 8.99|
|52 Week Range||7.61 - 19.99|
|Beta (5Y Monthly)||2.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.45|
Subscribe to Yahoo Finance Plus to view Fair Value for BCRX
The move by the FDA comes after the company voluntarily paused enrollment in multiple clinical trials over concerns about potential kidney dysfunction in patients.
RESEARCH TRIANGLE PARK, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences: The Bank of America Securities 2022 Healthcare Conference in Las Vegas, NV on Tuesday, May 10, 2022, at 11:00 a.m. ET. The RBC Capital Markets Global Healthcare Conference in New York on Wednesday, May 18, 2022 at 1:35 p.m. ET.The H.C. Wainwright Global Investment Conference – pre-recorded fireside chat available
The biotech whiffs on both revenue and profitability for its first quarter, and indicates more losses are in store.